BioSpace News Archive

Technological advancements and a rise in the prevalence of ophthalmic disorders are anticipated to boost the growth of the market.

SHINE Technologies, LLC, a next-generation nuclear technology company, announced Chris Vessell has joined as General Manager of the Therapeutics Division.

Acasti Pharma Inc. (Nasdaq: ACST and TSX-V: ACST) (“Acasti"; the “Company”), has retained one of the industry’s leading investor relations firms, Lytham Partners, LLC, to lead a strategic investor relations and shareholder communication program.

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (“4Front” or the “Company”), a vertically integrated, multi-state cannabis operator and retailer, today announced its financial results for the first quarter ended March 31, 2022 (“Q1 2022").

Aldeyra Therapeutics, Inc. announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference.

Ensysce Biosciences, Inc. announced the initiation of PF614-103, ‘A Randomized, Double-blind, Placebo- and Active-Controlled Crossover Study to Evaluate the Intranasal Abuse Potential of PF614 Compared with Immediate-Release Oxycodone and Placebo in Non-Dependent Recreational Opioid Users’ is being conducted by Dr. Glen Apseloff, from Ohio Clinical Trials.

MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended March 31, 2022, and highlighted recent corporate events.

ICON plc, a world-leading healthcare intelligence and clinical research organisation, announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the H.C. Wainwright Global Investment Conference on Tuesday, May 24, 2022, at 7.00am ET.

Transcat, Inc. reported financial results for its fourth quarter and fiscal year ended March 26, 2022.

Xcovery Holdings, Inc., an oncology focused bio-pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational New Drug application (IND) of BPI-442096 , a small molecule Src homology region 2 domain-containing phosphatase 2 (SHP2) inhibitor, in solid tumors.